Claims
- 1. A high throughput method of assaying compound(s) by determining their ability to modify the activity of an enzyme, comprising:
providing a modified double-stranded oligonucleotide sequence, the sequence having a complimentary sequence hybridized thereto to provide a double stranded sequence, the double-stranded oligonucleotide sequence further comprising an incorporated base analogue characterized by increased fluorescence when moved out of its normal helical position; contacting the modified double-stranded oligonucleotide sequence with an enzyme, said enzyme characterized by affecting the 3-dimensional position of the base analogue within the modified double-stranded oligonucleotide sequence, whereby the contacting is carried out in the presence of a compound(s) to be assayed; and determining whether the compound(s) affect(s) the enzyme based on a change in the levels of fluorescence of the incorporated base analogue.
- 2. The method of claim 1, wherein the double stranded sequence is attached to a surface.
- 3. The method of claim 2 wherein the surface is a non-porous planar surface.
- 4. The method of claim 1 wherein the assay is performed using a microarray.
- 5. The method of claim 1, wherein the assay is performed using robotics.
- 6. The method of claim 1, wherein the double stranded sequence is in solution.
- 7. The method of claim 1, wherein the enzyme is a methyltransferase.
- 8. The method of claim 7, wherein the methyltransferase is a cytosine-specific DNA methyltransferase.
- 9. The method of claim 8, wherein the cytosine-specific DNA methyltransferase is M.HhaI.
- 10. The method of claim 1, wherein the enzyme is a DNA-repair enzyme.
- 11. The method of claim 1, wherein the enzyme is a DNA modifying enzyme.
- 12. The method of claim 1, wherein the analogue can substitute specifically for a natural base in an enzymatic reaction involving nucleic acid replication, ligation and phosphorylation.
- 13. The method of claim 1, wherein the analogue is selected from the group consisting of formycin, 2-amino purine, ribonucleoside, and 2, 6-diamino ribonucleoside.
- 14. The method of claim 1, wherein the analogue is selected from the group consisting of formycin A, formycin B, oxyformycin B, toyocamycin, sangivamycin, pseudouridine, showdomycin, minimycin, pyrazomycin, 5-amino-formycin A, 5-amino-formycin B, 5-oxo-formycin A, 4-amino-pyrazolo [3, 4d] pyrimidine, 4,6-diamino-pyrazolo pyrimidine, 4-amino-6-oxo-pyrazolo [3, 4d] pyrimidine, 4-oxo-pyrazolo [3, 4d] pyrimidine, 4-oxo-6-amino-pyrazolo [3, 4d] pyrimidine, 4,6-dioxo-pyrazolo [3, 4d] pyrimidine, pyrazolo [3, 4d] pyrimidine, 6-amino-pyrazolo [3, 4d] pyrimidine, and 6-oxo-pyrazolo pyrimidine.
- 15. A method for determining the amount of a compound required to inhibit an enzyme that interacts with DNA comprising the steps of:
(a) combining a substrate with a liquid sample containing a known amount of an enzyme that interacts with DNA and a compound being assayed wherein the substrate has attached to a surface a known number of double stranded sequences which sequences comprise a base analogue characterized by increased fluorescence when moved out of its normal helical position; (b) allowing the enzyme, compound and sequences to interact over a sufficient period of time and under conditions such that the enzymes would move the analogue out of its normal helical position; (c) determining an increase in fluorescence relative to the known amount of fluorescence of the sequences; (d) repeating steps (a), (b) and (c) with different amounts of the compound until the amount of the compound needed to prevent an increase in fluorescence is determined by determining the amount of the compound required to inhibit the enzyme.
- 16. The method of claim 15 wherein the assay is performed using a microarray.
- 17. A method of assaying a plurality of compounds by determining their ability to modify the activity of an enzyme comprising:
(a) providing a modified double-stranded oligonucleotide sequence, the sequence, the sequence having a complimentary sequence hybridized thereto to provide a double stranded sequence, the double-stranded oligonucleotide sequence further comprising an incorporated base analogue characterized by increased fluorescence when moved out of its normal helical position; (b) contacting the modified double-stranded oligonucleotide sequence with an enzyme, said enzyme characterized by affecting the 3-dimensional position of the base analogue within the modified double-stranded oligonucleotide sequence, whereby the contacting is carried out in the presence of a plurality of the compounds; (c) determining whether any of the compounds in the plurality of compounds affects the enzyme based on a change in the levels of fluorescence of the incorporated base analogue. (d) if there is no change concluding that none of the compounds modifies the activity of the enzyme; (e) if there is a change dividing the compounds into two or more pools and assaying each pool separately by steps (a)-(c); (f) eliminating inactive compounds based on the results of the assays of the pools of step (e); (g) further dividing the remaining compounds into smaller pools and repeating the assay of steps (a)-(c) until the identity of the compounds having the ability to modify the activity of the enzyme is known.
- 18. The method of claim 17 wherein the plurality of compounds includes at least 100 compounds.
- 19. The method of claim 18 wherein the plurality of compounds includes at least 1000 compounds.
- 20 The method of claim 17 wherein the assay is performed using a microarray.
Government Interests
[0001] This invention was made, at least in part, with Government support under Grant No. MCB-9603567, awarded by the National Science Foundation. The Government may have certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60276875 |
Mar 2001 |
US |